(XT) iShares Exponential - Ratings and Ratios
Technology, Healthcare, Industrials, Consumer, Materials
Dividends
| Dividend Yield | 0.59% |
| Yield on Cost 5y | 0.82% |
| Yield CAGR 5y | -2.85% |
| Payout Consistency | 89.0% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 16.7% |
| Value at Risk 5%th | 29.0% |
| Relative Tail Risk | 5.75% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.82 |
| Alpha | 7.63 |
| CAGR/Max DD | 0.71 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.526 |
| Beta | 0.991 |
| Beta Downside | 1.004 |
| Drawdowns 3y | |
|---|---|
| Max DD | 22.09% |
| Mean DD | 4.37% |
| Median DD | 3.50% |
Description: XT iShares Exponential November 09, 2025
The iShares Exponential Technologies ETF (NASDAQ: XT) aims to track a specialized subset of the Morningstar Global Markets Index, allocating at least 80 % of its capital to the index’s component securities or to assets that closely mirror their economic characteristics.
Key quantitative details (as of Q3 2025) include an expense ratio of roughly 0.47 %, total assets under management near $1.2 billion, and a weighted average market-cap of about $250 billion, indicating a bias toward large-cap innovators.
Sector exposure is heavily tilted toward artificial-intelligence, robotics, and advanced materials, with the top five holdings-NVIDIA, Tesla, ASML, Advanced Micro Devices, and Shopify-accounting for roughly 30 % of the portfolio, reflecting the broader macro trend of rising global R&D spending and semiconductor demand.
Because XT’s performance is closely tied to the pace of AI adoption and the rollout of next-generation manufacturing technologies, investors should monitor leading-edge R&D intensity metrics and global semiconductor capacity utilization as forward-looking drivers.
For a deeper, data-driven breakdown of XT’s risk-adjusted performance, you might explore the analytics on ValueRay.
What is the price of XT shares?
Over the past week, the price has changed by +1.20%, over one month by +0.85%, over three months by +9.29% and over the past year by +21.82%.
Is XT a buy, sell or hold?
What are the forecasts/targets for the XT price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 81.1 | 7.7% |
XT Fundamental Data Overview December 05, 2025
Beta = 1.36
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 3.68b USD (3.68b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 3.68b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 3.68b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.67% (E(3.68b)/V(3.68b) * Re(9.67%) + (debt-free company))
Discount Rate = 9.67% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XT ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle